Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate

Published: Tuesday, October 08, 2013
Last Updated: Tuesday, October 08, 2013
Bookmark and Share
Collaboration for the development of an epigenetic innovative oncology target.

The Agency for Science, Technology and Research (A*STAR)’s Experimental Therapeutics Centre (ETC) and Debiopharm Group™ (Debiopharm) have announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

Under the terms of the agreement, Debiopharm and ETC will co-finance the discovery phase of the project, whilst Debiopharm will be in charge of development.

“This partnership aims to target tumors with genetic lesions. The use of epigenetic targets is emerging as an effective and valuable approach for personalized medicine strategies for cancer treatment,” said Andres McAllister, Chief Scientific Officer Research & Evaluation, Debiopharm International SA, “ETC represents the perfect partner to develop this project as they are experts in the field of oncology and possess the full range of drug discovery capabilities. Their situation within the Biopolis campus is a major asset for the development of new products.”

ETC is directed by Prof. Alex Matter who has a highly successful track record within the pharmaceutical industry.

He was the Global Head of Oncology Research for Novartis Pharmaceuticals Corporation and he played an important role in the success of several anticancer drugs, including Gleevec/Glivec® and more recently, Tasigna®.

Prof Matter was joined at ETC by a panel of seasoned industry colleagues and has put together a team of experts dedicated to the discovery and development of new medicines.

According to Prof Alex Matter, CEO, Experimental Therapeutics Centre, A*STAR: “This joint research collaboration will give both partners the opportunity to leverage on each other’s strengths, with the objective of creating new and more effective treatments against cancer.”

Rolland-Yves Mauvernay, President and founder of Debiopharm Group™ added: “We are very excited to be collaborating with ETC, top oncology and drug discovery experts. This partnership strengthens our presence in Asia in a highly dynamic area for innovation when it comes to the development of new drugs. Furthermore, this collaboration is in line with our strategy focusing on patients outcomes by offering more targeted oncology therapies.”

ETPL, the technology transfer arm of A*STAR, fosters strategic collaborations and deals between academia and industry.

ETPL bridged the interests of ETC and Debiopharm, and accelerated the research agreement and licensing deal between both parties in an effort to encourage more of such public-private partnerships.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™
Diagnoplex secures 1.3 million Swiss francs from financing round.
Friday, June 07, 2013
Debiopharm Group to Support Ascepion in the Development of Debio 1144
Development of Debio 1144 for the treatment of Chinese cancer patients.
Thursday, April 18, 2013
Chugai and Debiopharm Announce an Exclusive License Agreement for FF284
Chugai will grant Debiopharm an exclusive license to develop and commercialize FF284 in all countries.
Tuesday, January 08, 2013
First Patient Treated in Phase III Study with SC Administration of Debio 8206
Administration of Debio 8206 by SC route will prove very convenient in prostate cancer patients.
Thursday, December 27, 2012
Debiopharm, Immunexpress and Biocartis Announce Collaboration
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.
Wednesday, December 26, 2012
Debiopharm and Ascepion Announce an Exclusive License Agreement
Agreement for the development and commercialization of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases.
Tuesday, June 19, 2012
Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of Debio 0932
Company expects to initiate a combination Phase I/II study in NSCLC patients in the second quarter of 2012.
Tuesday, February 21, 2012
Debiopharm Group™ and Biocartis Enter Partnership to Enhance Personalized Medicine
The partners will furthermore cooperate in the field of companion diagnostics linked to the therapies developed by Debiopharm.
Friday, April 09, 2010
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos